Timefolio K-Bioactive ETF, Ranked No.1 in 3-Month Performance Among Active ETFs

Timefolio Asset Management announced on the 3rd that the 'Timefolio K-Bio Active ETF,' which invests in leading domestic bio and healthcare companies, has risen approximately 30% over the past three months, ranking first in returns among actively managed ETFs listed in Korea.

According to the Korea Exchange, as of the 2nd, the 'TIMEFOLIO K-Bio Active ETF' achieved a 3-month return of 29.67%. The 6-month return recorded was 35.05%.

This is an actively managed ETF product that focuses on investing in Korea's representative bio and healthcare companies in areas such as new drug and biosimilar companies, medical devices/equipment, and digital healthcare. Major investment stocks include Yuhan Corporation, Alteogen, Celltrion, Samsung Biologics, and Rigachem Bio.

Lee Jung-wook, head of the ETF division at Timefolio Asset Management, said, "Bio and healthcare stocks showed strong price increases centered on bio stocks with potential technology transfers amid an imminent interest rate cut." He added, "With the U.S. Congress pushing the Biosecurity Act to restrict transactions with Chinese bio companies, Korean Contract Development and Manufacturing Organizations (CDMOs) are expected to benefit directly or indirectly."

The bio healthcare industry has relatively high entry barriers due to complex terminology, unpredictable clinical trial results, and approval uncertainties. Actively managed ETFs that can invest according to market conditions can be an effective investment alternative in the bio sector.

This content was produced with the assistance of AI translation services.